What is BRVE's current stock price?

BRVE (Braveheart Bio, Inc.) is currently trading at $21.41 with a market cap of $1.51B.

What sector is Braveheart Bio, Inc. in?

Braveheart Bio, Inc. (BRVE) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

BRVE Braveheart Bio, Inc.

NASDAQHealthcare

$21.41+1.76%OpenMarket Cap: $1.51B

As of 2026-10-22 12:05

Why BRVE matters now

Braveheart Bio, Inc. (BRVE) is a US stock in Healthcare. The latest InvestLog snapshot shows $21.41 with +1.76% on the session and $1.51B in market capitalization.

The latest indexable market news headline is "Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026" from GlobeNewsWire.

Latest News

Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026GlobeNewsWire · 2026-10-30

Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026GlobeNewsWire · 2026-10-30

Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The ProductSeeking Alpha · 2026-10-20

Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What HappenedDefense World · 2026-10-02

Braveheart Bio to Participate in Stifel Cardiometabolic ForumGlobeNewsWire · 2026-09-16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ

Beta

0.00

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.